Completed PHASE2 INTERVENTIONAL 1-arm NCT00694863

Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy (ACTHiMeN)

Treatment With Synthetic Adrenocorticotropic Hormone (ACTH) in Patients With Membranous Nephropathy and High Risk for Renal Failure. A Pilot Study

Sponsor: Dutch Kidney Foundation

Conditions Idiopathic Membranous Nephropathy

Interventions tetracosactide hexacetaat

Updated 6 times since 2017 Last updated: Jan 4, 2013 Started: Jul 31, 2008 Primary completion: Dec 31, 2010 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Idiopathic Membranous Nephropathy and is currently completed. Dutch Kidney Foundation leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Mar 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dutch Kidney Foundation
Radboud University Medical Center

Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nijmegen, Netherlands